Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Repare Therapeutics Inc. (NASDAQ: RPTX) will participate in two investor conferences in September 2022. The first event is the Morgan Stanley 20th Annual Global Healthcare Conference on September 14 at 2:55 p.m. ET in New York. The second is the Guggenheim Nantucket Therapeutics Conference on September 28 at 8:00 a.m. ET in Nantucket, MA. Live webcasts will be available on the company’s website, and replays will be accessible for 90 days. Repare focuses on precision oncology, utilizing its SNIPRx® platform to develop targeted cancer therapies.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details for the fireside chats are as follows:

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Wednesday, September 14, 2022
Time: 2:55 p.m. Eastern Time
Location: New York, NY

Guggenheim Nantucket Therapeutics Conference
Date: Wednesday, September 28, 2022
Time: 8:00 a.m. Eastern Time
Location: Nantucket, MA

A live webcast of the fireside chats can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcasts will be archived on the Company’s website for 90 days.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development partnered with Roche; RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development; RP-2119, a Polθ inhibitor program in ongoing IND-enabling studies; as well as several additional, undisclosed preclinical programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005031/en/

Repare Contact:

Robin Garner

Executive Director and Head of Investor Relations

Repare Therapeutics Inc.

info@reparerx.com



Investors:

Matthew DeYoung

Argot Partners

repare@argotpartners.com



Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Repare Therapeutics Inc.

FAQ

When is Repare Therapeutics participating in the Morgan Stanley Conference?

Repare Therapeutics will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 2:55 p.m. ET.

What is the date and time for Repare Therapeutics at the Guggenheim Nantucket Conference?

Repare Therapeutics will be at the Guggenheim Nantucket Therapeutics Conference on September 28, 2022, at 8:00 a.m. ET.

How can I access the webcasts for Repare Therapeutics' investor conferences?

Live webcasts for the conferences can be accessed on Repare Therapeutics' website in the Investor section.

What is the focus of Repare Therapeutics Inc.?

Repare Therapeutics focuses on precision oncology and the development of targeted cancer therapies using its SNIPRx® platform.

What are some of the therapies in Repare Therapeutics' pipeline?

Repare's pipeline includes camonsertib (RP-3500), RP-6306, and several other preclinical programs.